




FIG. 1


	TIS + CT	CT
	Intention-To-Treat (ITT) Set	
	n=226	n=227
MPR, % (95% CI)^a	56.2 (49.5-62.8)	15.0 (10.6-20.3)
Difference, % (95% CI); <i>P</i> value ^b	41.1 (33.2-49.1); <i>P</i> < .0001	
OR (95% CI); <i>P</i> value ^b	7.5 (4.8-11.8); <i>P</i> < .0001	
pCR, % (95% CI)	40.7 (34.2-47.4)	5.7 (3.1-9.6)
Difference, % (95% CI); <i>P</i> value ^b	35.0 (27.9-42.1); <i>P</i> < .0001	
OR (95% CI); <i>P</i> value ^b	11.5 (6.2-21.5); <i>P</i> < .0001	

^a Assessed by blinded independent review committee (IRC)

^b I-sided

Abbreviations: MPR, major pathological response; OR, odds ratio; pCR, pathological complete response.

FIG. 2



*By American Joint Committee on Cancer Staging Manual 8th Edition, Investigators were also permitted to choose 5-fluorouracil plus cisplatin, but this option was not used. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ESCC, esophageal squamous cell carcinoma; F, fraction; MPR, major pathological response; ORR, objective response rate; pCR, pathological response rate; PET/CT, positron emission tomography/computed tomography; Q3W, every three weeks; SUV, standardized uptake value.

FIG. 3




FIG. 4A-4B




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9